C
VRTX icon

CEDRUS’s Vertex Pharmaceuticals VRTX Stock Holding History

CEDRUS’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$360K Buy
774
+120
+18% +$57.6K 0.13% 124
2024
Q2 		$307K Sell
654
-42
-6% -$18.2K 0.15% 120
2024
Q1 		$291K Sell
696
-95
-12% -$40.2K 0.16% 121
2023
Q4 		$322K Buy
+791
New +$292K 0.2% 114

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

CEDRUS's VRTX Position: Q3 2024 in Review

CEDRUS increased its Vertex Pharmaceuticals (VRTX) stake by 18% in Q3 2024, buying an estimated $57.6K and bringing the position to 774 shares worth $360K. The position accounts for 0.13% of the portfolio, ranked #124.

CEDRUS first reported a position in VRTX in Q4 2023 and has held it in 4 quarters since. 1,546 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

  • CEDRUS held 774 shares of Vertex Pharmaceuticals worth $360K as of Q3 2024.
  • CEDRUS bought 120 Vertex Pharmaceuticals shares in Q3 2024, an estimated $57.6K.
  • Vertex Pharmaceuticals made up 0.13% of CEDRUS's portfolio in Q3 2024, its #124 holding.
  • CEDRUS first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 4 quarters since.
  • 1,546 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on CEDRUS's 13F filing for Q3 2024, filed 18 Oct 2024.